Invitation to presentation of Xbrane Biopharma's interim report January - September 2026 on October 30, 2026

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Friday, October 30th, 2026, at 09.00 a.m. CET. Xbrane will publish the company’s interim report January – September 2026, on Friday, October 30, 2026, at 8.00 a.m. CET.

Martin Åmark, CEO, and Jane Benyamin, CFO/IR, will present the interim report January – September 2026, followed by a Q&A session. The presentation will be in English.

If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.

Q3 Report 2026

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

Call access

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Hagastaden, Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com